Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06747858 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Study acronym: LunairCF
StatusRecruiting
PhasePhase 2
Started2024-12-12
View on ClinicalTrials.gov ↗
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.

Amendment record

Amended 6 times since 2024-12-20; most recent filed 2026-05-06. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-05-06
Amendment Study Status, Oversight, Study Description, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v6
2025-10-07
Amendment Study Status, Oversight, Contacts/Locations v5
2025-07-30
Amendment Study Status, Oversight, Contacts/Locations v4
2025-04-14
Amendment Study Status, Oversight, Contacts/Locations v3
2025-02-19
Amendment Study Identification, Study Status, Oversight, Contacts/Locations v2
2025-01-20
Amendment Study Status, Contacts/Locations v1
2024-12-20
Original filing
Trial Details
NCT Number NCT06747858
Lead Sponsor Arcturus Therapeutics, Inc.
Conditions Cystic Fibrosis, CFTR Gene Mutation
Enrollment 33 participants
Start Date 2024-12-12
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-08